Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Ionis Pharmaceuticals

Ionis Pharmaceuticals
PUBLIC STATUS
701-800 EMPLOYEES
IONS STOCK SYMBOL
15 INVESTMENTS
$61.69 SHARE PRICE (As of Wednesday Closing)
Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with partner Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market. ATTR amyloidosis drug Tegsedi (inotersen) was approved in 2018 and cardiology drug Waylivra was approved in Europe in 2019.

Formerly Known As
Isis Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 2855 Gazelle Court
  • Carlsbad, CA 92010
  • United States

+1 (760) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Ionis Pharmaceuticals’s full profile, request a free trial.

Ionis Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$48.27 - $86.58 $8.68B $62.91 $3.13 985K 141M

Ionis Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 7,020,358 6,246,340 5,953,756 5,595,181
Revenue 821,033 599,674 514,179 372,776
EBITDA 181,575 (18,839) 36,338 (9,638)
Net Income 429,806 273,741 346 (60,400)
Total Assets 2,894,989 2,667,784 1,322,774 912,467
Total Debt 674,327 646,720 607,477 589,105
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ionis Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Ionis Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Ionis Pharmaceuticals Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 00000000 00.000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
000000000 00000000 Corporation Pasadena, CA 000 00.000 0000
0000000-00000 0000 Corporation New York, NY 00000 00000 000000000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
To view this company’s complete list of competitors, request access »

Ionis Pharmaceuticals Investments & Acquisitions (15)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 10-Nov-2017 000000000 Biotechnology 00000 00000 00.0
0000000 00000 0000 06-Sep-2017 00000 00000 00 00.00 Diagnostic Equipment 0. 00000 00000000 00
00000000 01-Oct-2016 000000000000000000 00000 Biotechnology 00000 00000 00.0
0000000 0000000000 04-Oct-2012 000 0000 Drug Discovery 0. 00000 00000000 00
Altair Therapeutics 12-Nov-2009 Early Stage VC 0000 Pharmaceuticals
To view this company’s complete investment and acquisition history, request access »

Ionis Pharmaceuticals Exits (5)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 12-Nov-2009 00000 00000 00 0000 Completed
  • 5 buyers
000000 00000000000 18-Dec-2007 00000 00000 00 Completed
  • 3 buyers
000000000 00000000 16-Nov-2007 00000 00000 00 000.00 Completed
  • 5 buyers
0000000 0000000000 15-Mar-2004 00000 00000 00 0000 Completed
  • 10 buyers
Protogene Laboratories 01-Jan-1999 Early Stage VC 0000 Completed
  • 3 buyers
To view this company’s complete exits history, request access »

Ionis Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Ionis Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Ionis Pharmaceuticals Executive Team (10)

Name Title Board
Seat
Contact
Info
Stanley Crooke Ph.D Chief Executive Officer & Chairman
Elizabeth Hougen Chief Financial Officer & Chief Accounting Officer
Brett Monia Ph.D Chief Operating Officer & Board Member
Frank Bennett Ph.D Senior Vice President, Research & Franchise Leader for Neurological Programs
Sanjay Bhanot Chief Medical Officer & CardioMetabolic Franchise Leader

2 Former Executives

You’re viewing 5 of 10 executives. Get the full list »

Ionis Pharmaceuticals Board Members (10)

Name Representing Role Since Contact
Info
0. 00000 00000000 00 Ionis Pharmaceuticals Board Member & Strategic Advisor 000 0000
00000 00000 00.0 Ionis Pharmaceuticals Chief Operating Officer & Board Member 000 0000
000000000 0000 00 Self Board Member 000 0000
0000 000000 Self Board Member 000 0000
000000 00000 000 Ionis Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »